Pricing
Prices are indicative MRP and may vary by pharmacy. Trend compares against the last recorded price.
All price changes →Save on this medicine
Same active ingredient — pay up to 92% less
These brands contain the same active ingredient (Sofosbuvir). Strength and form may differ — confirm substitution with your doctor or pharmacist before switching.
Indications & Uses
Soventa is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
One 400 mg tablet taken once daily with or without food. Should be used in combination with Ribavirin or in combination with Pegylated Interferon and Ribavirin for the treatment of CHC.Recommended combination therapy: (HCV Mono-infected and HCV/HIV-1 Co-infected)- Genotype 1 or 4: Sofosbuvir + Peginterferon alfa + Ribavirin for 12 weeks Genotype 2: Sofosbuvir + Ribavirin for 12 weeks Genotype 3: Sofosbuvir + Ribavirin for 24 weeks Sofosbuvir in combination with Ribavirin for 24 weeks can be considered for CHC patients with genotype 1 infection who are Interferon ineligibleShould be used in combination with Ribavirin for treatment of CHC in patients with hepatocellular carcinoma awaiting liver transplantation for up to 48 weeks or until liver transplantation whichever occurs firstA dose recommendation cannot be made for patients with severe renal impairment or end stage renal disease
Side Effects
Common side effects with Buviren plus Ribavirin (occurring in 20% or more of patients, all severity levels) were fatigue and headache. When Buviren was combined with Peginterferon alfa and Ribavirin, patients more often reported fatigue, headache, nausea, insomnia, anemia, itching, weakness, rash, reduced appetite, chills, flu-like symptoms, fever, diarrhea, low neutrophil counts, muscle aches, and irritability.
Cautions & Contraindications
Warnings & Precautions
Bradycardia with amiodarone: Combining amiodarone with Buviren and another direct-acting antiviral (DAA) can cause serious, symptomatic slowing of the heart rate. This risk is higher in patients who are also on beta blockers, or who have underlying heart conditions and/or advanced liver disease. For this reason, giving amiodarone alongside Buviren plus another DAA is not recommended. If no other treatment option is available, heart function should be monitored closely.
Contraindications
When Sofosbivur is used in combination with Ribavirin or Peginterferon alfa/ Ribavirin, the contraindications applicable to those agents are applicable to combination therapies. Sofosbuvir combination treatment with Ribavirin or Peginterferon alfa/Ribavirin is contraindicated in women who are pregnant or may become pregnant and men whose female partners are pregnant, because of the risks for birth defects and fetal death associated with Ribavirin.